Bristol Myers Squibb's Krazati, in combination with cetuximab, failed to significantly improve survival rates in metastatic colorectal cancer patients compared to chemotherapy. Meanwhile, the European Medicines Agency has initiated a rolling review of Revolution Medicines' experimental treatment for pancreatic cancer. Additionally, HitGen announced that its partner BioAge Labs has commenced a Phase 2 clinical trial for BGE-102, an oral inhibitor targeting cardiovascular risk.
